Table 2.

Summary of studies reporting use of LAIs for recent‐onset or early‐initiation therapy in schizophrenia

Reference	Patient population	Treatment	Assessments	Outcomes
Barrio et al., 201361	26 patients with recent onset treated with LAI versus 26 control recent onset treated with oral	Case–control study of LAI versus oral for 2 years	PANSS total and subscales, PAS, hospitalization, remission	LAI showed significant improvement in PANSS and subscales, PAS; higher remission, lower hospital
Dubois et al., 201462	155 patients with schizophrenia (≤3 years) versus 253 (>3 years)	Observational study of LAI for 12 or 24 months from the TIMORES and eSTAR studies	CGI‐S, GAF, hospitalization, remission	Significant benefits for early for CGI‐S and GAF, remission; number of hospital days
Emsley et al., 200863	50 newly diagnosed patients	Open‐label treatment with LAI for 2 years	Remission, relapse, PANSS, CGI‐S, function, SF‐12	Remission in 64%, and 97% maintained remission; remission associated with improvements in function
Emsley et al., 200864	50 patients with ≤12 months since diagnosis and ≤12 weeks drug; 54% were drug naïve	Open‐label study of LAI × 24 months	Clinical outcomes, EPS, prolactin	72% completed 24 months; 78% had a response; 64% achieved a remission
Emsley et al, 200865	50 patients with ≤12 weeks drug treatment; 46% were antipsychotic naïve	Open label with LAI × 24 months; compared with oral antipsychotic	PANSS, EPS, BMI	LAI group had fewer discontinuations, lower PANSS scores, higher remission rate, lower relapse rate; EPS lower with LAI but BMI higher
Lasser et al., 200748	66 young adults with ≥4 weeks of antipsychotic treatment; mean duration of 131 days	Open‐label trial of LAI for 50 weeks	PANSS, SF‐36	Significant improvement from baseline for PANSS and SF‐36
Macfadden et al., 201049	57 recent diagnosed (≤3 years) versus 266 late diagnosed (>3 years)	Open‐label treatment with LAI for 1 year	Relapse, PANSS, CGI‐S	Recent diagnosed had greater improvement in PANSS and CGI‐S
Malla et al., 201366	85 patients in the early phase of schizophrenia spectrum disorder	Randomized to oral or LAI treatment for 2 years	PANSS, CGI‐S	Improvement in both groups, but no differences between groups
Napry‐eyenko et al., 201067	294 patients with ≤2 years duration of schizophrenia	Open‐label study of LAI for 6 months	PANSS, CGI‐S, GAF, SF‐36	Significant improvement in all parameters from baseline
Rabinowitz et al., 201168	294 patients with ≤2 years duration of schizophrenia	Open‐label study of LAI for 6 months	Premorbid Adjustment Scale (PAS), PANSS, CGI‐S, GAF, SF‐36	Premorbid functioning associated with better response
Olivares et al., 200969	Patients with recent (≤2 years) or long term (>2 years)	Observational study of LAI for 24 months	CGI‐S, GAF, hospitalization	Greater improvement with recent for CGI‐S, hospital rate and days; GAF not different
Parellada et al., 200550	382 patients with ≤3 years diagnosis; mean 1.5 years	Open‐label trial of LAI for 6 months	PANSS total and subscales, CGI‐S, GAF, QoL, patient satisfaction	Significant improvement from baseline in PANSS total and subscale scores, CGI‐S, QoL, patient satisfaction
Sliwa et al., 201270	Compared recent diagnosis (n = 216, ≤5 years) with chronic illness (n = 429, >5 years)	Open‐label LAI and followed for 1 year	Tolerability	Improved tolerability with LAI compared with baseline levels
Tiihonen et al., 201171	2588 hospitalized for the first time for schizophrenia	Registry‐based linkage study of depot versus oral treatment for mean follow up of 2 years	Hospitalization and discontinuation	Rehospitalization was one‐third with depot versus oral medication
Viala et al., 201252	25 schizophrenia patients hospitalized for the first time	Open‐label study of switch from oral to LAI	CGI, GAF at 6, 12 and 18 months; hospitalization	Significant improvement from baseline in CGI‐S and GAF; 16% relapsed; fewer and shorter hospitalizations